Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Korea biotech races to seize MASH market as Rezdifra ignites demand

8 November 2026 · By · Wire by Fusion42

Published

8 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

South Korea

◆ Source

Read at biz.chosun.com →

◆ Verified

Fusion42 · 8 November 2026 · Fusion42 review

The MASH treatment market is expanding rapidly with Rezdifra from Madrigal Pharmaceuticals achieving blockbuster sales after FDA accelerated approval. Korean biotech firms Hanmi Pharmaceutical and D&D Pharmatech are also demonstrating promising clinical trial results, intensifying global competition in developing effective MASH therapies.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You need to act fast in metabolic liver disease treatments as Korean biotech firms push new candidates that challenge the current US market leader. Your chance to lead relies on proving your drug’s superior long-term benefits beyond Rezdifra’s initial success.

◆ Coverage

1 source · 8 Nov 2026

◆ Related on Wire

◆ Topics

Biotechmashbiotechdrug-developmentclinical-trialskorea